Title |
Long-term efficacy and safety of iloperidone: an update
|
---|---|
Published in |
Neuropsychiatric Disease and Treatment, February 2014
|
DOI | 10.2147/ndt.s37824 |
Pubmed ID | |
Authors |
Jeffrey T Rado, Philip G Janicak |
Abstract |
Schizophrenia is a devastating neuropsychiatric disease with a worldwide prevalence of approximately 0.5%-1%. Since many patients do not achieve adequate symptom relief from available agents, alternate pharmacotherapeutic approaches are needed. In this context, iloperidone was recently approved by the US Food and Drug Administration for the treatment of schizophrenia. This paper first reviews its pharmacodynamic and pharmacokinetic profiles, emphasizing their clinical relevance. Next, it summarizes the literature on its acute and maintenance efficacy, safety, and tolerability. It then considers pharmacogenetic data which may help to predict response and risk of cardiac arrhythmias with this agent. Finally, it critically positions iloperidone relative to other first- and second-generation antipsychotics. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 3 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 3 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 20 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 4 | 20% |
Researcher | 4 | 20% |
Student > Doctoral Student | 2 | 10% |
Student > Bachelor | 2 | 10% |
Student > Master | 2 | 10% |
Other | 2 | 10% |
Unknown | 4 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 8 | 40% |
Biochemistry, Genetics and Molecular Biology | 3 | 15% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 10% |
Psychology | 2 | 10% |
Engineering | 1 | 5% |
Other | 0 | 0% |
Unknown | 4 | 20% |